Abbreviations & Acronyms ADT = androgen deprivation therapy CCI = Charlson Comorbidity Index CI = confidence interval CSS = prostate cancer-specific mortality EBRT = external beam radiation therapy HR = hazard ratio LHRH = luteinizing hormonereleasing hormone mCRPC = metastatic castration-resistant prostate cancer OS = overall survival PSADT = prostate-specific antigen doubling time PSA = prostate-specific antigen RP = radical prostatectomy SEARCH = Shared Equal Access Regional Cancer Hospital SEER = Surveillance, Epidemiology and End Results VA = Veterans Affairs Objectives: To evaluate the impact of previous local treatment on survival in men with newly diagnosed metastatic castration-resistant prostate cancer. Methods: We carried out a retrospective study of patients newly diagnosed with metastatic castration-resistant prostate cancer in the year 2000 or later from eight Veterans Affairs Medical Centers. Patients were categorized based on prior local therapy (none, prostatectomy AE radiation or radiation alone). Overall and cancer-specific survival was estimated by the Kaplan-Meier method. Cox proportional hazards regression models were used to test the association between prior local treatment and survival. Results: Of 729 patients, 284 (39%) underwent no local treatment, 176 (24%) underwent radical prostatectomy AE radiation and 269 (37%) underwent radiation alone. On multivariable analysis, men with prior prostatectomy had improved overall (hazard ratio 0.71, P = 0.005) and cancer-specific survival (hazard ratio 0.55, P < 0.001) compared with men with no prior local therapy. This improvement in overall (hazard ratio 0.89, P = 0.219) and cancer-specific survival (hazard ratio 0.87, P = 0.170) was not seen in men with prior radiation alone. After further adjusting for comorbidity with the Charlson Comorbidity Index, patients with prior prostatectomy still had improved overall survival (hazard ratio 0.70, P = 0.003), whereas this was not seen in patients who received prior radiation alone (hazard ratio 0.88, P = 0.185). Conclusions: Independent of patient-and disease-related factors, men with metastatic castration-resistant prostate cancer who had undergone prior radical prostatectomy have improved overall and cancer-specific survival compared with those with no prior local therapy.
Introduction
Despite significant advances in chemotherapy and androgen deprivation therapies, survival for men with metastatic prostate cancer has not significantly improved over the past 20 years. 1 With modern combination systemic therapy, survival rates can be improved. 2, 3 However, despite this combination, the death rate remains high and there remains no cure. As such, there has been a growing interest in recent years in the role of prior local therapy on outcomes among men with metastatic prostate cancer when the tumor was presumed to be clinically localized.
castration-sensitive prostate cancer has also been associated with a decrease in the risk of death. 6, 7 Outside of patients with castration-sensitive disease, the effects of previous local treatment on survival in men with advanced mCRPC disease remain unknown. 8 To address this gap, we studied the impact of previous local treatment on OS and CSS in men with M0/MX CRPC who progressed to mCRPC. To do this, we identified men who were patients at VA Medical Centers newly diagnosed with mCRPC who had undergone either no prior local therapy, local therapy with RP AE radiation (XRT) or local therapy with XRT alone. We hypothesized that patients with previous local therapy would have improved OS.
Methods

Study cohort
After obtaining institutional review board approval, we collected data on patients who were diagnosed with CRPC, regardless of the type of primary treatment, in the year 2000 or later from eight VA Medical Centers (Durham and Asheville, NC; Palo Alto, San Francisco, West Los Angeles and San Diego, CA; Portland, OR; and Augusta, GA) from the SEARCH database. Data abstracted included information on patient age, year of diagnosis, race, PSA level, PSADT, tumor grade, time from ADT to CRPC, time from CRPC to metastasis and type of metastasis. Comorbidity burden at diagnosis was ascertained using the Deyo-Klabunde modification of the CCI, utilizing secondary diagnosis codes. CCI scores were calculated for each patient, excluding the diagnosis of prostate cancer. CRPC was defined as a PSA rise of ≥2 ng/mL and 25% from the nadir PSA after ADT while being castrate. 9 Castration was defined as a serum testosterone level <50 ng/dL, bilateral orchiectomy, or continuous receipt of LHRH agonist or antagonist. In total, 1292 men had documented CRPC with an absence of a positive imaging test for distant metastases before a CRPC diagnosis (i.e. M0 CRPC). The rationale to exclude men with metastasis before CRPC is to generate a cohort of men who all had an initial diagnosis of mCRPC without having had metastases prior, thereby controlling for metastatic tumor burden as best as possible. Of these 1292 men with non-mCRPC, 558 (43.2%) did not develop metastatic disease during the followup period and were excluded. We excluded patients who were missing data on race (n = 5) and PSA (n = 15), which left a total study cohort of 729 patients (Fig. 1 ).
Statistical analysis
Characteristics were compared among patients who had either no previous local treatment, RP with or without postoperative XRT or XRT alone using Kruskal-Wallis tests for continuous variables and v 2 -tests for categorical variables. Univariable and multivariable Cox proportional hazards models were used to test the association between prior local treatment (none, RP AE XRT or XRT) and our primary end-point of the time from diagnosis of mCRPC to OS and our secondary endpoint of CSS. Death from prostate cancer was defined as having metastases showing progression after hormonal therapy without another obvious cause of death. Multivariable models were adjusted for age at mCRPC diagnosis (continuous), year of mCRPC diagnosis (continuous), biopsy grade group (1 vs 2-3 vs 4-5 vs unknown/no biopsy), months from ADT to CRPC (continuous), months from CRPC to metastases (continuous), PSA at mCRPC (continuous, log-transformed), and PSADT at mCRPC diagnosis (>9 months vs <9 months vs missing), type of metastases (bone vs soft tissue vs bone and soft tissue vs unknown) and treatment center. Kaplan-Meier curves were created for each end-point, and differences between previous local therapy and the various outcomes were tested using the log-rank test. In order to assess for possible differences in OS and CSS in patients who had received RP alone versus those who had received RP AE XRT, we repeated the analysis using four groups, no prior local therapy, RP, RP AE XRT and XRT alone. Stata version 14.0 (StataCorp, College Station, TX, USA) was used for all statistical analyses. P < 0.05 was the threshold for statistical significance.
Results
Baseline characteristics at time of metastases
Of the 729 patients with mCRPC, there were 284 (39%) who underwent no local treatment, 176 (24%) that had prior RP AE XRT and 269 (37%) had prior XRT alone ( Table 1 ). All patients who underwent local therapy did so before development of CRPC. A total of 99 patients underwent RP + XRT (56%), and among these patients, 94 (95%) underwent either adjuvant or salvage XRT and five (5%) underwent salvage RP. A total of 364 patients underwent radiation therapy. Of these patients, 297 (81.6%) underwent EBRT, 21 (5.8%) underwent brachytherapy alone, and 19 (5.2%) patients underwent a combination of brachytherapy and EBRT. Radiation technique is unknown for 27 (7.4%) patients. At the time of mCRPC diagnosis, patients with no prior local therapy were older than patients with prior local therapy with RP AE XRT or prior XRT alone (80 vs 72 vs 77 years; P < 0.001), were diagnosed with metastases in 6 vs 34.1 ng/ mL; P < 0.001), had high-grade tumors (36% vs 24% vs 30% grade group 4-5; P = 0.033) and had longer time from ADT to CRPC (50 vs 40 vs 32 months; P = 0.001). Among patients who received primary treatment, the median time to ADT from primary localized treatment was 34 months in patients receiving RP AE XRT and 27 months in patients receiving XRT alone (P = 0.001). There was no significant difference in race, time from CRPC diagnosis to time of metastasis diagnosis, or in type of metastasis at diagnosis. The majority of patients (63%) were on continuous ADT with the remaining on intermittent ADT.
Time from mCRPC to OS (primary outcome)
We compared OS rates between patients who had received previous local therapy and those who had not, from the time of metastasis diagnosis. The median follow-up time after metastasis was 14.9 months (interquartile range 4.8-27.0) among patients who survived. During follow up, 588 (81%) patients died. Patients who had received RP AE XRT had a decreased risk of death on univariable analysis (HR 0.58, 95% CI 0.47-0.72, P < 0.001). Results on multivariable analysis remained statistically significant (HR 0.71, P = 0.005). On univariable analyses, patients who had received prior XRT had a decreased risk of death (HR 0.83, 95% CI 0.69-0.99, P = 0.043); however, this decreased risk of death was no longer significant on multivariable analysis (HR 0.89, 95% CI 0.73-1.07, P = 0.219). These results are shown in Table 2 Table S1 ). HRs for the association between primary treatment and time from metastasis to all-cause mortality are shown in Table S2 .
Time from mCRPC to prostate cancer-specific survival
We next compared CSS rates between patients who had received previous local therapy and those who had not, from the time of metastasis diagnosis. Of the 588 men who died, 543 died of prostate cancer (92%). Patients who had received RP AE XRT had a decreased risk of CSS on univariable analysis (HR 0.55, 95% CI 0.44-0.69, P < 0.001). Analogous to the results with OS, results remained statistically significant on multivariable analysis (HR 0.68, 95% CI 0.53-0.87, P = 0.002). Similar to the OS results, patients who had received prior XRT had a decreased risk of CSS on univariable analyses (HR 0.80, 95% CI 0.66-0.96, P = 0.019); however, this decreased risk was no longer significant on multivariable analysis (HR 0.87, 95% CI 0.71-1.06, P = 0.170). HRs for the association between primary treatment and time from metastasis to CSS are shown in Table S3 . These results are illustrated in Table 2 and Figure 2b . We then assessed for possible differences in CSS in patients who had received RP alone versus those who had received RP + XRT. Compared with patients with RP alone, there was no improvement in CSS in patients with prior RP + XRT on univariable (HR 0.97, 95% CI 0.67-1.40, P = 0.88) or multivariable (HR 0.97, 95% CI 0.66-1.42, P = 0.88) analysis ( Fig. 3 ; Table S1 ).
Comorbidity, and overall and prostate cancerspecific survival
To account for the possibility that differences in health status accounted for this difference in survival, we further adjusted for CCI in our models to assess differences in time from development of metastases to OS and CSS (Table 3) . After adjusting clinical and pathological characteristics along with CCI, results were nearly identical to those without adjusting for CCI in that patients with prior local therapy with RP AE XRT had a decreased risk of OS (HR 0.70, 95% CI 0.55-0.88, P = 0.003), whereas this was not seen in patients who received prior XRT alone (HR 0.88, 95% CI 0.72-1.07, P = 0.185). Similarly, adjusting for CCI in addition to clinical and pathological characteristics did not affect the association between prior local therapy with RP AE XRT and lower CSS (HR 0.66, 95% CI 0.52-0.85, P = 0.001) or the null association between prior XRT alone and CSS (HR 0.86, 95% CI 0.7-1.05, P = 0.142).
Discussion
The role of RP in multimodal treatment for advanced prostate cancer has gained increasing interest. Various retrospective studies have shown that after the development of metastases, men who had previously undergone local therapy had improved survival, and in men with metastatic prostate cancer at diagnosis, definitive local therapy was associated with improved survival. 6, 7, 10 Six prospective randomized controlled trials evaluating the role of therapy to the primary tumor in the metastatic setting are currently ongoing. However, these previous studies and trials have not included men with mCRPC, the most advanced form of prostate cancer. On multivariable analysis, controlling for patient-and diseaserelated factors, including comorbidity, we found that men with mCRPC who had undergone prior local therapy when the disease was presumed to be localized, particularly with RP, had improved OS and CSS. The current data support continued research to evaluate the potential benefit of removal of the primary tumor.
There is a growing biological rationale for local management of systemic disease. Despite systemic chemohormonal therapy, aggressive prostate cancer often remains within the primary tumor site. 11, 12 Cancer cells that leave the primary tumor can seed metastases in distant organs through circulating tumor cells. 13 In a bidirectional process, these circulating cells can also colonize their tumors of origin.
14 This interaction of metastatic and primary tumor cells promotes disease progression, androgen independence and the development of metastasis. 15 Retrospective reviews have expanded on these pre-clinical models. In the metastatic setting, analysis of SEER data and secondary analysis of results from several trials on metastatic patients have shown a correlation with improved survival outcome in men who underwent prior primary therapy before a diagnosis of metastatic disease. 6, 16 Retrospective analysis of the SEER database and Munich Cancer Registry on RP in men after a diagnosis of metastatic prostate cancer has similarly shown associations with improved survival. 17, 18 Although these studies have provided a rationale for further studying the impact of local therapy in advanced prostate cancer, the inherent patient and tumor selection bias associated with survivorship outcomes in observational studies limits the ability to make meaningful recommendations based on them. 19, 20 Recent studies have examined the feasibility of RP in men with metastatic hormone-sensitive prostate cancer, with all showing complication rates comparable with those reported in a series of RP in high-risk localized disease. [21] [22] [23] [24] Similar results have also been shown in those with castration-resistant metastatic disease. 25 The finding of improved OS in men newly diagnosed with mCRPC who had undergone prior RP is consistent with previous reports in men newly diagnosed with metastatic castration-sensitive disease. Interestingly, we found that this associated benefit was similar in men who had received prior RP alone and prior RP AE XRT. The impact of previous XRT in men with metastatic prostate cancer remains controversial. Although two studies showed that among men with metastatic prostate cancer, those who previously received XRT had improved survival relative to no treatment, 7, 18 one study found that these men actually had worse survival compared with those who received either RP or no prior local therapy. 6 Furthermore, in one of the studies where XRT was associated with improved survival, a propensity score-matched analysis showed that this benefit was still less than that seen after RP. 10 One possible explanation for the improved survival after metastasis in men receiving RP compared with men receiving XRT is tumor selection bias. Patients receiving XRT might have done so because of unresectability by RP or large tumor burden in the primary. Alternatively, younger, healthier patients might opt for surgery at the time of initial diagnosis and in turn live longer than those undergoing XRT. Other authors have suggested that tumor self-seeding of the irradiated prostate leads to increased metastatic potential of the cancer cells. However, these results remain speculative, and three ongoing clinical trials (STAMPEDE, NCT00268476; PEACE-1, NCT01957436; and HORRAD, NTR271) investigating the role of local XRT in metastatic disease are ongoing, with early results from STAMPEDE showing improved survival in the cohort who had XRT.
26
The present findings are consistent with the growing literature showing an association between improved survival and previous local therapy in men with advanced prostate cancer, specifically mCRPC. Although the theory of circulating tumor cells provides a biological rationale for the present findings, alternative explanations are plausible. Our multivariable model attempted to adjust for various patient-and tumor-specific factors including comorbidity; however, it is possible that healthier men selectively underwent previous local therapy. Although we attempted to control for comorbidity with the CCI, this tool primarily focuses on disease presence and not severity. Therefore, it is unable to capture the spectrum of severity within a given comorbid condition. However, previous studies have shown a differential prognostic impact of comorbidity, with concurrent comorbidities having a low impact in patients with advanced cancer and highly morbid cancer, such as mCRPC. 27 Alternatively, our cohort consisted of men newly diagnosed with mCRPC (i.e. they had all been diagnosed with non-mCRPC prior). It is possible that men who received local therapy, who were diagnosed in later years, were followed more closely and had their metastases detected earlier. Indeed, the PSA levels at mCRPC diagnosis were lower, as was the time from ADT to CRPC and CRPC to metastases (though this might also reflect more aggressive disease). Although we controlled for these factors, it remains possible that a lead-time bias exists, which might have influenced these results. As newer, more metastatic-sensitive, imaging modalities develop, the heterogeneity of the M0 CRPC population will become better elucidated. An examination of our findings within this context will help clarify these results.
Despite the strengths afforded by the present study, including a VA cohort from multiple centers and the large number of African American and non-African American patients, it had several limitations. First, this was a retrospective study that relied on the procurement of information through interpretation of patient medical records. Although our inclusion of only VA patients is a strength for evaluating patients who have equal access, it does make the present results potentially difficult to extrapolate to other patient populations. Importantly, because these results were outside of a clinical trial setting, treatment with various anticancer therapies was not standardized. However, most patients in the present study were diagnosed in in an era that pre-dated the modern use of agents, such as abiraterone and enzalutamide. Given the modest improvements in survival associated with these pre-modern chemotherapy agents, it is unlikely that differences in chemotherapy use would entirely explain these results. Also, although we controlled for comorbidities, and patient and clinical factors, it is possible that residual confounding explains our results. Finally, as noted above, imaging for metastases was not uniform and we cannot rule out lead-time bias.
Multimodal treatment including local radiation or surgery for advanced prostate cancer has gained increasing interest. No prior study or trial has evaluated the potential impact in patients with progressive M0 CRPC. Independent of patientand disease-related factors, including comorbidity, we found that men with M0 CRPC who progressed to mCRPC and who had undergone prior RP had improved OS and CSS when compared with men with no prior local therapy. These data suggest the need for prospective evaluation to determine the potential impact of removal of the primary tumor, even in the most advanced stages of prostate cancer. 
Supporting information
Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Table S1 . HRs for the association between primary treatment and time from metastasis to all-cause mortality and PC-specific mortality. Table S2 . HRs for the association between primary treatment and time from metastasis to all-cause mortality. However, readers should be aware of the selection used in this study. Selection of patients was based on nonmetastatic CRPC, excluding patients with positive imaging for distant metastases before the CRPC diagnosis and nonmetastatic CRPC patients who did not develop metastases during follow up. The authors comment that this was done to control for metastatic tumor burden, but this selection is susceptible to introducing important bias.
In fact, this study states that men who progress from M0 CRPC to M1 CRPC have improved survival when they have undergone prior local therapy (radical prostatectomy) compared with those who were treated with androgen deprivation therapy (ADT) for localized disease. Patients receiving prostatectomy might have more favorable patient and tumor characteristics than those receiving no local treatment (or radiotherapy or multimodal therapy), and do have more favorable patient and tumor characteristics than those receiving ADT for localized disease. 2 In contrast, patients with improper imaging are also included. With the improvement of imaging (e.g. prostatespecific membrane antigen positron-emission tomography), many of the so-called "non-metastatic" CRPC patients will harbor M1 disease. 4 Additionally, the group of patients with progression under ADT to CRPC after radical prostatectomy without local recurrence could be different from those where the prostate is still in situ. Patients with a prostate in place could have disease progression inside the prostate without metastatic lesions, as well as patients with local recurrence after radical prostatectomy or radiotherapy. The authors justly mentioned the possibility for an earlier detection bias in patients with prior local therapy. In the real clinical setting, this could be advantageous. Data provided to fully evaluate the different additional treatments, radiotherapy modalities and settings are, however, insufficient.
With the development of novel potent (systemic) treatments in the past decade, one could question if prior local treatment is even necessary, or, if we should select a maximized multimodal treatment to gain control of these aggressive tumors. Current study favors the latter; however, we should never forget the potential bias in carrying out retrospective studies. In the future, we should evaluate if cytoreduction of the tumor bulk could be an option to prevent resistance of some aggressive tumor cells to radiotherapy and systemic agents, and also prevent local progression and complications when progressing to a more advanced disease stage.
